Project Grant R44AI186802
Award Date 8/18/26
Completion Date 7/31/29
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $245,250 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how sensory neuron release of substance P stimulates B cell immunoglobulin E production in asthma. The research will examine the mechanism by which the neuropeptide substance P, released from neurons sensitized during asthmatic...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic Arizona $638,403 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the roles of group 2 innate lymphoid cells (ILC2s) in type 2 immunity and asthma. The project examines immunological mechanisms underlying airway inflammation in asthma patients, focusing on how ILC2s—which rapidly produce type 2 cytokines—regulate adaptive immune responses in the lungs and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin–Madison $1,650,321 on August 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct longitudinal research on early life epithelial development and asthma risk through the Childhood Allergy and the Neonatal Environment (CANOE) study. The award funds analysis of serial nasal cell samples collected from study participants beginning at birth through age 5 years to...
- The National Institute of Allergy and Infectious Diseases awarded La Jolla Institute for Immunology (doing business as La Jolla Institute for Allergy & Immunology) $764,868 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate house dust-mite allergen-specific T cell subsets in allergy and asthma. The research explores mechanisms and cell types that drive either natural tolerance or allergen sensitization and asthma development, focusing on...
- The National Institute of Allergy and Infectious Diseases awarded the University of Utah $423,500 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, R21AI189586) to develop and validate a high-throughput screening system and orthogonal assays for discovery of small molecule inhibitors of the IL-25 signaling pathway. The research targets IL-25-mediated inflammatory diseases, including allergic asthma, and aims to establish a hit identification and...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $250,000 to the University of Michigan under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 21, 2025, for research aimed at developing diagnostic and prognostic tools for food allergies. The project, which concludes on July 31, 2026, focuses on creating an immunological niche (IN) scaffold technology to identify immunological markers that distinguish between mild and severe...
- The National Institute of Allergy and Infectious Diseases awarded a cooperative agreement totaling $564,548 to the Regents of the University of Michigan on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into how bone-marrow multipotent progenitors bearing the FcεRI receptor drive mast-cell–mediated allergic responses at mucosal sites. The project addresses the gap between current therapies that target downstream mast-cell...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $236,660 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate IL-33-dependent and IL-33-independent pathways in allergic asthma. The project examines how IL-33 signaling drives type-2 inflammatory responses in allergic asthma and why blockade of IL-33 has produced mixed clinical trial results despite its position as an upstream therapeutic target. The...
- The National Institute of Allergy and Infectious Diseases awarded National Jewish Health $776,394 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate prenatal programming of immune cells in asthma, specifically how maternal exposure to diesel exhaust particles impairs embryonic growth and alters mast cell function to drive airway remodeling. The research uses a mouse model to establish mechanistic linkages between maternal environmental...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $598,906 on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of respiratory viral infections in hospitalized children. The research examines how early-life respiratory tract infections contribute to asthma development by analyzing nasal transcriptomes in children hospitalized with bronchiolitis or asthma. The project team...